Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: CuttIng ballooN angioplaSTy Combined wITh Paclitaxel drUg coaTed Balloon Angioplasty, an observatIONal Clinical Study

Dialysis Access Malfunction Clinical Trial

— INSTITUTION  

Official title:

Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: CuttIng ballooN angioplaSTy Combined wITh Paclitaxel drUg coaTed Balloon Angioplasty, an observatIONal Clinical Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05018962
• Other study ID #: 2017/2046
• Status: Completed
• Phase: Phase 2
• Start date: September 8, 2017
• Est. completion date: March 18, 2020

Study information

• Verified date: August 2021
• Source: Singapore General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine if cutting balloon angioplasty combined with DEB angioplasty provides a higher primary patency after treatment of recurrent stenoses compared with cutting balloon angioplasty or angioplasty using DEB alone in the venous outflow AVFs. For cutting balloon angioplasty in venous stenosis, the primary patency after 12 months is 55-60% (9,16) and in recurrent stenoses up to 48%(10). We hypothesise that DEB angioplasty after cutting balloon angioplasty leads to improved primary patency at 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: March 18, 2020
• Est. primary completion date: April 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Recurrent stenoses (within 1 year after angioplasty) in the venous outflow of AVFs for dialysis access (> 0.5cm from AV anastomosis up to cephalic arch)
• Successful guidewire crossing of target lesion
• = 21 years old
• Informed and valid consent given.
• Patient willing and able to return for follow up .

Exclusion Criteria:

1. Thrombosed AVFs or occlusions in the access circuit

2. Significant cephalic arch (central perpendicular portion of the cephalic vein) or central vein stenoses.

3. > 3 stenosed segments (lesions are considered separate if they are separated by at least 2 cm normal vessel.)

4. Only potential target lesion located in cephalic arch, central veins or anastomotic lesions.

5. Only de novo stenoses identifiable as target lesion.

6. Target lesion resistant to cutting balloon angioplasty (>30% residual stenosis with incomplete effacement of the lesion during cutting balloon angioplasty)

7. Target lesion not treatable with the available sizes of cutting balloon (4-7mm) and drug eluting balloon (up to 8mm) so native reference vessel <3 mm or need for DEB balloon >8mm.

8. Lesion in excess of 8 cm

9. Unable to take dual antiplatelet therapy for 1 month and/or aspirin for 6 months

10. Coagulopathy (PT or PTT >1.5 times the median of normal range) or thrombocytopenia (platelet count <50,000 /µL) that cannot be managed adequately with periprocedural transfusion.

11. Patient on Warfarin.

12. Known allergy to iodinated contrast that cannot be managed adequately with pre-procedure medication.

13. Allergy / contraindication to dual anti-platelet therapy (aspirin and clopidogrel or ticlopidine) or paclitaxel.

14. Acute infection over proposed puncture site.

15. Women who are breastfeeding, pregnant or planning on becoming pregnant during study.

16. Participant with medical conditions, which in the opinion of the investigator may cause non-compliance with protocol.

17. Currently participating in an investigational drug, biologic or device trial that may have an impact on the dialysis access or previous enrolment in this study.

Related Conditions & MeSH terms

• Arteriovenous Fistula
• Constriction, Pathologic
• Dialysis Access Malfunction
• Fistula

Intervention

Device:
• Cutting balloon followed by paclitaxel coated balloon
Cutting balloon followed by paclitaxel coated balloon

Locations

Country	Name	City	State
Singapore	Singapore General Hospital	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
Singapore General Hospital	Boston Scientific Corporation

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Target lesion primary patency	Target lesion primary patency	1 year
Secondary	Circuit primary patency	Circuit primary patency	1 year
Secondary	Target lesion primary assisted patency		1 year